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Abstract
Mechanisms underlying the poor breast cancer prognosis among obese women are unresolved. 
DNA methylation levels are linked to obesity and to breast cancer survival. We hypothesized that 
obesity may work in conjunction with the epigenome to alter prognosis. Using a population-based 
sample of women diagnosed with first primary breast cancer, we examined modification of the 
obesity-mortality association by DNA methylation. In-person interviews were conducted 
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approximately 3 months after diagnosis. Weight and height were assessed [to estimate body mass 
index (BMI)], and blood samples collected. Promoter methylation of 13 breast cancer-related 
genes was assessed in archived tumor by methylation-specific PCR and Methyl Light. Global 
methylation in white blood cell DNA was assessed by analysis of long interspersed elements-1 
(LINE-1) and with the lumino-metric methylation assay (LUMA). Vital status among 1308 
patients (with any methylation biomarker and complete BMI assessment) was determined after 
approximately 15 years of follow-up (N = 194/441 deaths due to breast cancer-specific/all-cause 
mortality). We used Cox proportional hazards regression to estimate hazard ratios (HRs) and 95 % 
confidence intervals (CIs) using two-sided p values of 0.05. Breast cancer-specific mortality was 
higher among obese (BMI ≥ 30) patients with promoter methylation in APC (HR = 2.47; 95 % CI 
= 1.43–4.27) and TWIST1 (HR = 4.25; 95 % CI = 1.43–12.70) in breast cancer tissue. Estimates 
were similar, but less pronounced, for all-cause mortality. Increased all-cause (HR =1.81; 95 % CI 
= 1.19–2.74) and breast cancer-specific (HR = 2.61; 95 % CI = 1.45–4.69) mortality was observed 
among obese patients with the lowest LUMA levels. The poor breast cancer prognosis associated 
with obesity may depend on methylation profiles, which warrants further investigation.
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Introduction
Breast cancer (BC) remains the second leading cause of cancer-related death in the United 
States (US), with an estimated 40,000 deaths occurring in 2015 [1]. Overweight and obesity 
are associated with poor BC prognosis [2], but the mechanisms underlying this association 
are unresolved. In the US, one-third of the population is obese [3], and approximately 3.1 
million are BC survivors [4]. Thus, understanding how obesity influences BC prognosis 
could have public health and clinical impact.
Epigenetics is an attractive source of novel biomarkers which exploits the stability of DNA, 
the reversible nature of epigenetic aberrancies, and can be measured in a range of tissues, 
including blood [5]. Changes to the epigenome could serve as a useful target for predicting 
BC prognosis. DNA methylation has been the most studied epigenetic mechanism in human 
populations and includes both hypermethylation and hypomethylation [6]. Gene-specific 
methylation in target tissues has been widely investigated, and hypermethylation of tumor 
suppressor genes has been associated with BC prognosis in several studies, including our 
own [7, 8]. Global DNA hypomethylation has been evaluated to a lesser extent but is a 
common phenomenon in carcinogenesis [9] and has similarly been linked to poor BC 
prognosis [10].
Given BC prognosis is likely influenced by multiple factors, it is plausible that obesity 
works in conjunction with the epigenome to alter prognosis. Specifically, adiposity may 
promote tumor progression through the production of excess estrogen [11], which may 
induce promoter hypermethylation of several important tumor suppressor genes [12]. 
Despite the strong biologic plausibility, to our knowledge, no epidemiologic study has 
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examined the interaction between obesity and DNA methylation on BC prognosis. This 
study examined, in a population-based sample of women with first primary BC, whether the 
association between obesity and BC mortality was modified by gene-promoter methylation 
of a panel of 13 BC-related genes measured in tumor tissue (APC, BRCA1, CCND2, CDH1, 
DAPK1, ESR1, GSTP1, HIN1, CDKN2A, PGR, RARβ, RASSF1A, and TWIST1). We also 
determined whether the obesity-mortality association was modified by global DNA 
methylation using two methods to assess white blood cell methylation: long interspersed 
elements-1 (LINE-1) which approximates levels in repetitive elements [13] and the 
luminometric methylation assay (LUMA) which estimates methylation at CCGG sites [14]. 
We hypothesized that obesity and aberrant methylation would work synergistically to 
increase both all-cause and BC-specific mortality following a diagnosis of BC.
Methods
This project draws on the resources of the follow-up component of Long Island. Breast 
Cancer Study Project (LIBCSP) is a population-based study. Details of the study participants 
and design for this component have been previously described [15–17]. Written informed 
consent was obtained for all subjects, and Institutional Review Board approval was obtained 
from all participating institutions.
Study participants
Eligible participants for the LIBCSP follow-up study were English-speaking women 
residing in Nassau and Suffolk counties of Long Island, NY, who were newly diagnosed 
with a first primary in situ or invasive BC between August 1, 1996 and July 31, 1997. 
Women were identified using rapid case ascertainment via daily or weekly contact with 
pathology departments of all 28 hospitals on Long Island and three tertiary care hospitals in 
New York City. The final LIBCSP follow-up sample consisted of 1508 women with BC, of 
which 1273 (84 %) had invasive BC as confirmed by review of the medical records. At 
diagnosis, participants were aged 20–98 years and predominately postmenopausal (67 %) 
and white (94 %), which was consistent with the underlying racial/ethnic distribution in 
these counties at the time of data collection.
Data collection
Obesity and other covariates—Self-reported weight and height in the year prior to 
diagnosis were assessed as part of the baseline interviewer-administered structured 100-min 
questionnaire, which was completed, on average, within 3 months of diagnosis. These 
assessments were used to calculate the body mass index (BMI) for each participant [weight 
(kg)/height (m2)], as a measure of obesity. Participants were additionally queried on their 
demographic characteristics (including age, race/ ethnicity, income, and education), medical 
histories (including family history of BC, exogenous hormone use, and mammography 
screening), and other potential prognostic factors as previously detailed [15–17]. Medical 
records were also abstracted for clinically relevant prognostic factors (including treatment 
and hormone receptor status).
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Medical records data—As part of the LIBCSP protocol, medical records were abstracted 
at baseline and again at the 5-year follow-up to determine tumor characteristics (e.g., ER/PR 
status, tumor size, and nodal involvement) and treatment regimen of the first primary BC 
diagnosis.
Gene-specific promoter methylation—Archived FFPE tumor tissue of the first 
primary BC was obtained, and DNA extraction was performed, as previously described [18]. 
Thirteen genes known to be involved in breast carcinogenesis, and frequently methylated in 
promoter regions, were selected for assessing interactions with obesity. Promoter 
methylation of ERa, PR, and BRCA1 was determined by methylation-specific (MSP)-PCR 
and was dichotomized (i.e., methylated vs. unmethylated) based on the presence or absence 
of the PCR band [18, 19]. Methylation status of the 10 remaining genes was assessed by the 
Methyl Light assay [20, 21]. The percentage of methylation was calculated by the 2−ΔΔCT 
method, where ΔΔCT = (CT,Target − CT,Actin)sample − (CT,Target − CT,Actin)full methylated DNA 
[22] and multiplying by 100. Using a 4 % cut-off, we dichotomized into methylated or 
unmethylated cases as previously reported [23].
Global methylation—For 73.1 % of women with BC, trained phlebotomists obtained a 
non-fasting 40 mL blood sample at the baseline interview, and DNA was isolated as 
previously described [24]. Details of LUMA and LINE-1 assessment in the LIBCSP have 
been described previously [14]. Briefly, LUMA followed the modified protocol described by 
Bjornsson et al. [25] and was expressed as a percentage based on the following equation: 
methylation methylation(%) = [1 − (HpaII ΣG/ΣT)/(MspI ΣG/ΣT)]* 100 [25]. Four CpG 
sites in the promoter region of LINE-1 were assessed using a pre-validated pyrosequencing-
based methylation assay [20] and were individually analyzed as a T/C single-nucleotide 
polymorphism using QCpG software (Qiagen). These data were subsequently averaged to 
provide an overall percentage 5mC status.
Mortality—Vital status through the end of 2011 was determined through the NDI as 
previously reported [26]. Briefly, after approximately 14.7 (0.2–15.4) years of follow-up, 
among the 1308 patients with any global or gene-specific methylation assessments and 
complete BMI data, we identified 441 who died from all causes and 194 whose deaths were 
related to BC. BC-related deaths were determined using the International Classification of 
Diseases (codes 174.9 or C-50.9).
Statistical analysis
Among 1308 women with any methylation biomarker and complete BMI assessment, Cox 
proportional hazards regression [27] was used to estimate hazard ratios (HR) and 95 % 
confidence intervals (95 % CI) for the association between BMI, methylation status (global 
and gene-specific), and mortality (all-cause and BC-specific) over the follow-up period of 
more than 15 years. All statistical test were two-sides (a priori p = 0.05). The proportional 
hazards assumption was assessed using exposure interactions with time [27]. We observed 
non-proportionality for CDKN2A, PR, and RARβ; as such, exposure-time interactions were 
included in each of the models for those genes [27]. We observed no violations with 
remaining genes, global markers, or BMI.
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For interaction analyses, we assessed BMI continuously and using the standard World 
Health Organization classifications (<25.0 kg/m2; 25.0–29.9 kg/m2; and ≥30 kg/m2). 
Methylation of gene promoters were classified as methylated or unmethylated as described 
above and global methylation markers (LUMA and LINE-1) were dichotomized at the 
median. Effect measure modification on the multiplicative scale between BMI and 
methylation was evaluated using the likelihood ratio test with a 0.05 significance level, 
comparing proportional hazards regression models with and without the cross-product terms 
[28].
All models were initially adjusted for age at diagnosis (continuous). We further considered 
inclusion of other covariates in multivariate models if they were related to either the 
exposure, modifier, or outcome. These variables included family history of BC (yes/no), 
history of benign breast disease (yes/no), smoking (ever/never), and race (white, black, and 
other). Covariates were removed from the multivariate model using backward elimination. 
Variables remained in the final model if their exclusion changed the effect estimate by > 
10 % [31]. None of these covariates met our criteria and thus all models were adjusted for 
age at diagnosis only.
Given our baseline BMI measures reflects body size in the year prior to diagnosis, we did 
not consider tumor characteristics (e.g., tumor stage, grade, size, and nodal involvement)or 
hormone receptor status as potential confounders of the association between BMI, 
methylation, and mortality. These covariates are on the causal pathway between BMI and 
survival and adjustment for them would result in biased parameter estimates [29, 30]. Even 
upon adding hormone receptor status (any ER/PR positive vs. ER and PR negative) to the 
multivariate model, we observed no substantial difference in the effect estimates. Further, 
our findings restricted to women with invasive tumors did not vary substantially from those 
among all women, likely due to the low proportion of in situ cases (~15 %) in our study 
population. Our analyses therefore include both invasive and non-invasive cases. All 
statistical analyses were performed using SAS statistical software version 9.4 (SAS Institute, 
Cary, NC).
Results
Distribution of clinical characteristics
Table 1 shows the distribution of clinical characteristics among the 1308 women diagnosed 
with first primary BC with any information on DNA methylation status (gene-specific or 
global methylation) and BMI. At diagnosis, most patients had a BMI of ≥25, no family 
history of BC, tumor size <2 cm, and no nodal involvement. The distributions of clinical 
characteristics by gene-specific methylation marker have been previously described [7, 8].
BMI, gene-promoter methylation, and global methylation: associations with all-cause and 
BC-specific mortality
In Table 2, we provide effect estimates for obesity and methylation markers, separately, in 
association with mortality after approximately 15 years of follow-up among our LIBCSP 
cohort of 1308 women newly diagnosed with first primary BC in 1996–1997. These 
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LIBCSP-based associations were previously reported for obesity with follow-up through 
2002 [32], and for the gene-specific methylation markers with follow-up through 2005 [7, 
8], but have now been updated with extended follow-up through 2011. We also newly 
describe associations between global methylation markers (LUMA and LINE-1) and 
mortality through 2011. Our updated estimates suggest increased mortality in association 
with BMI and most methylation markers and are similar to the previously reported estimates 
in this same cohort based on shorter follow-up time [7, 8, 32] (Table 2).
Associations between BMI, gene-promoter methylation, and mortality
As shown in Table 3, the association between obesity and mortality following a BC 
diagnosis was modified by promoter methylation status of two genes, APC and TWIST1 (p 
< 0.05 for multiplicative interaction). Among obese patients (defined as a BMI ≥ 30) with an 
unmethylated APC promoter, all-cause mortality was not increased (HR = 0.99; 95 % CI = 
0.64–1.53). In contrast, the corresponding effect estimate for methylated APC was increased 
two-fold (HR = 1.97; 95 % CI = 1.33–2.09). Similar, patterns of association were observed 
for breast cancer-specific mortality, but the effect sizes were more pronounced 
(unmethylated APC HR = 0.81; 95 % CI = 0.38–1.76 vs. methylated APC HR = 2.47; 95 % 
CI = 1.43–4.27).
For TWIST1, we observed a more than three-fold increased risk of dying at the end of 
follow-up among obese patients with a methylated TWIST1 promoter (HR = 3.21; 95 % CI 
= 1.51–6.83), whereas the corresponding effect estimate for an unmethylated TWIST1 
promoter was less pronounced (HR = 1.19; 95 % CI = 0.87–1.63). A similar, but stronger, 
association between obesity, TWIST1 methylation and BC-specific mortality was observed 
(HR = 4.25; 95 % CI = 1.43–12.70), although it was less precise.
CYCLIND2, GSTP1, and HIN1 promoter methylation also appeared to modify the 
associations between obesity and BC-specific mortality, but the interaction was of borderline 
significance (p < 0.10).
Associations between BMI, global methylation, and mortality
We observed multiplicative interaction between BMI, LUMA, and all-cause mortality and 
BC-specific mortality following a BC diagnosis (p < 0.05). For example, we observed an 
80 % increase in all-cause mortality among obese patients with low LUMA levels (HR = 
1.81; 95 % CI = 1.19–2.74) (Table 4). Among obese patients with high LUMA, however, the 
estimate was less pronounced and imprecise (HR = 1.23; 95 % CI = 0.87–1.73). Similarly, 
BC-specific mortality was increased more than twofold in obese patients with low LUMA 
(HR = 2.61; 95 % CI = 1.45–4.69), whereas the corresponding estimates among those with 
high LUMA were less pronounced (HR = 1.50; 95 % CI = 0.87–2.60).
We found no interaction between BMI, LINE-1, and mortality among women with BC.
Discussion
We are the first to report in a population-based cohort of women with first primary BC, all-
cause mortality after 15 years of follow-up was increased two-fold among obese participants 
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with methylated APC or TWIST1 promoters. Effect estimates were more pronounced for 
BC-specific mortality. We similarly observed two- and three-fold increases in all-cause and 
BC-specific mortality, respectively, among obese participants with the lowest levels of 
global methylation assessed using LUMA. Our findings suggest that the association between 
BMI and BC mortality may depend upon methylation profiles and warrant further 
investigation.
Several studies, including our own [7, 8, 32], support positive associations between obesity 
and mortality [33], as well as gene-specific methylation and prognosis [23]. However, to our 
knowledge, no previous study has considered interaction between obesity, gene methylation, 
and mortality following BC diagnosis despite strong biologic plausibility. There are several 
mechanisms thought to influence the adverse role of excess adiposity on BC prognosis. 
Increased circulating hormones and reduced sex hormone binding globulin are strong 
possibilities [34, 35]. Excess estrogen is known to promote tumorigenesis [36, 37] and may 
induce aberrant DNA methylation, altering several genes implicated in breast carcinogenesis 
[38, 39]. For example, estrogen-induced promoter hypermethylation of CDH1 and p16/
CDKN2A has been previously reported [12]. Taken together, these results suggest that the 
mechanism underlying the obesity-mortality association may be facilitated and/or altered by 
estrogen-mediated methylation changes.
In our findings reported here, elevated BMI was more strongly associated with mortality 
among BC patients with methylated APC and TWIST1. The APC tumor suppressor gene 
gives rise to familial adenomatous polyposis and its role in sporadic colorectal tumors is 
well documented [40]. Data show that APC may similarly be involved in breast 
carcinogenesis [41] although the frequency of inactivation is unresolved. Our observation of 
increased mortality among obese women with BC when methylation is present could reflect 
synergy between adipose-induced estrogen exposure and inactivation of the APC tumor 
suppressor; this is likely facilitated by improper TATA-binding in the promoter and reduced 
expression [42]. Although adiposity is positively associated with mortality overall in women 
with BC, we observed a reversal of the association when APC methylation was not present. 
This may suggest that activation of APC alleviates the deleterious effect of adipose-induced 
estrogen on overall and BC-specific mortality. TWIST1 is an anti-apoptotic and pro-
metastatic transcription factor, overexpressed in BC. Methylation of its gene promoter has 
frequently been observed in malignant breast tissue [42]. While we found substantial 
increases in mortality following BC diagnosis among obese patients with TWIST1 
methylation, the underlying biology is uncertain. TWIST1 is thought to function as an 
oncogene given its role in suppressing apoptosis and promoting metastasis. However, it has 
been suggested that methylation of the TWIST1 promoter provides breast epithelial cells 
with a selective advantage during breast carcinogenesis [43] and may explain the synergy 
observed with obesity in this study. Further, there appears to be little correlation between 
TWIST1 methylation and gene expression [44, 45].
To our knowledge, no previous study has evaluated associations between LUMA and BC 
prognosis. While LINE-1 hypomethylation has been associated with poor prognosis in 
epithelial cancers [46, 47], we identified only one investigation of BC where LINE-1 
hypomethylation was associated with decreased survival in younger (<55 years) women [5]. 
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In our population-based sample of women with BC, we did not find associations between 
global methylation and mortality when considering main effects for LUMA or LINE-1, 
although we did observe interaction between LUMA and BMI in relation to mortality. While 
typically global DNA hypomethylation increases genomic instability leading to the 
activation of oncogenes and silencing of tumor suppressors [48], LUMA measures levels of 
5-mC in the CmCGG motif which may result in approximation of methylation levels at gene 
promoters [14]. Thus, low LUMA may associate with better prognosis [49]. Our findings of 
worse prognosis among obese patients with low LUMA levels may be due to differences in 
our comparison groups. In the presence of low LUMA, obesity may be particularly 
deleterious, whereas in presence of high LUMA (and higher genomic instability), the 
additional risk of death from obesity is minimal. LINE-1 retrotransposon activity may be 
triggered by stress, including oxidative stress and exposure to DNA damaging agents leading 
to cancer initiation and progression [50, 51]. Given adiposity is linked to inflammation and 
oxidative damage, the lack of interaction between BMI and LINE-1 was surprising. 
However, among older patients LINE-1 hypomethylation is likely a bystander of age-
dependent tumor development [5] and may not be predictive of prognosis in the LIBCSP 
study population, which consists of mostly older women.
Our prospective, population-based study has numerous strengths. We are the first to examine 
the potential relationship between obesity, methylation (gene-specific and global) and BC 
survival, and in a comparatively large population-based sample of women diagnosed with a 
first primary BC with methylation markers and 15 years of follow-up. Our reliance on 
recalled weight and height is a potential limitation of this study. However, anthropometric 
data were obtained systematically by trained interviewers [15], and previous studies have 
found that self-reported anthropometric measures are reasonably accurate when compared 
with clinical measurements taken at the same time [52]. With regard to estimating gene-
specific methylation, we were unable to obtain archived tumor tissue for all LIBCSP cases 
potentially resulting in selection bias; nonetheless, our population-based sample of BC cases 
is among the largest with information on methylation status. Our panel of 13 biologically 
relevant genes limited the number of mechanistic pathways we could evaluate. Employing 
global methylation markers helps to overcome many of the limitations encountered using 
gene-specific markers, but it is unknown whether methylation levels in surrogate tissue 
correlate with levels in target tissue [53]. The LIBSCP study population is primarily 
comprised white women, which is the largest racial group of BC survivors in the US [54]. 
While our findings do not apply to African-American women, who are at greatest risk of 
death from BC, the underlying biologic pathways driving the association between obesity 
and mortality are unlikely to vary by race and may be relevant for all demographic groups. 
The racial homogeneity of our study population limits our ability to explore potential 
variation by intrinsic subtype (luminal A, luminal B, HER2, and triple negative), with known 
variation in prognostic outcomes. Yet, the largest subtype of BC diagnosed among US 
women of any race is ER+PR+ [55], which continues to increase with time [56] and is the 
predominant subtype of BC diagnosed among our study participants. Although we 
considered hormone receptor status as a potential confounder in the study reported here, we 
did not find that this tumor characteristic influenced our effects estimates. We did not 
consider more finely categorized breast cancer subtypes, which may have influenced our 
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findings. However, hormone receptor-positive tumors (ER+ or PR+) strongly correlate with 
the Luminal subtypes, which are associated with better prognosis. Similarly, the hormone 
receptor-negative tumors strongly correlate with both the HER2+ and triple-negative 
subtypes, which have been linked to poorer outcomes. Finally, although invasive cases have 
worst prognosis overall compared to in situ cases, both groups were included in our analysis. 
We calculated the frequency of methylation in the two groups independently (data not 
shown) and found similar prevalence (average difference across all genes was 5 %). These 
data support the hypothesis that in DNA methylation occurs prior to disease onset and are 
unlikely to be influenced by tumor aggressiveness. We have included in Supplemental Table 
1 associations for APC, TWIST1, and LUMA among invasive cases only.
In summary, we are the first to show that promoter methylation of APC and TWIST1, as 
well as levels of global methylation assessed using LUMA, may modify the well-established 
association between obesity and mortality following a BC diagnosis. Pending additional 
replication, our findings could help to identify women with BC who would most greatly 
benefit from increased surveillance. Our results may also provide clues to mechanistic 
pathways by which obesity influences BC prognosis.
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Table 1
Distribution of clinical characteristics among the 1308 participants with any information on methylation 
(gene-specific and/ or global) and body mass index in a population-based cohort of women diagnosed with 
first primary breast cancer, Long Island Breast Cancer Study Project
Covariate N (%)
Age at diagnosis
    <50 years 373 (28.5)
    ≥50 years 935 (71.5)
Menopausal status
    Premenopausal 401 (31.3)
    Postmenopausal 880 (68.7)
Family history of breast cancer
    No 1025 (80.8)
    Yes 243 (19.2)
Body mass index (BMI)
    BMI < 25 kg/m2 584 (44.7)
    BMI 25–29.9 kg/m2 423 (32.3)
    BMI ≥ 30 kg/m2 301 (23.0)
Cancer type
    In situ 203 (15.5)
    Invasive 1105 (84.5)
Estrogen receptor status
    Positive 653 (74.5)
    Negative 223 (25.5)
Progesterone receptor status
    Positive 564 (64.4)
    Negative 312 (35.6)
Tumor size
    <2 cm 473 (65.9)
    ≥2 cm 245 (34.1)
Nodal involvement
    0 548 (75.9)
    1 174 (24.1)
Treatment type
    No chemotherapy 538 (60.1)
    Chemotherapy 357 (39.9)
    No radiation 356 (39.6)
    Radiation 542 (60.4)
    No hormone therapy 335 (38.0)
    Hormone therapy 547 (62.0)
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